NDM-1 in Traveler, Canada | CDC EID

EID Journal Home > Volume 17, Number 2–February 2011

Volume 17, Number 2–February 2011
Dispatch
New Delhi Metallo-β-Lactamase from Traveler Returning to Canada1
Gisele Peirano, Jasmine Ahmed-Bentley, Neil Woodford, and Johann D. Pitout

Author affiliations: Calgary Laboratory Services, Calgary, Alberta, Canada (G. Peirano, J.D. Pitout); University of Calgary, Calgary (G. Peirano, J.D. Pitout); DynaLife Diagnostic Laboratories Services, Edmonton, Alberta, Canada (J. Ahmed-Bentley); and Health Protection Agency, London, UK (N. Woodford)

Suggested citation for this article

Abstract
An Escherichia coli isolate with New Delhi metallo-β-lactamase was isolated from a patient with pyelonephritis and prostatitis who returned to Canada after recent hospitalization in India. The patient was successfully treated with ertapenem and fosfomycin. This patient highlights the role of international travel in the spread of antimicrobial drug resistance and blaNDM-1.

The Enterobacteriaceae, particularly Escherichia coli and Klebsiella pneumoniae, are among the most common causes of serious hospital- and community-acquired bacterial infections in humans. Resistance to antimicrobial agents in these species has become increasingly prevalent. Of special concern is the development of resistance to the carbapenems; this development is caused by bacterial carbapenemases. These drugs are often the last line of effective therapy for treating infections caused by multidrug-resistant Enterobacteriaceae. Three types of β-lactamases inactivate the carbapenems: K. pneumoniae carbapenemases, metallo-β-lactamases (MBLs), and oxacillinases. The 2 most reported MBLs are the VIM and IMP types, which until recently have been mostly associated with Pseudomonas aeruginosa and Acinetobacter spp., although VIM-2 has spread among Enterobacteriaceae in Greece and, to a lesser extent, Italy (1).

Recently, a new type of MBL, New Delhi metallo-β-lactamase (NDM-1), in bacteria (K. pneumoniae and E. coli) recovered from a patient from Sweden who was hospitalized in New Delhi, India, was described (2).We characterized a carbapenem-resistant E. coli isolate from the urine of a patient with pyelonephritis and prostatitis who returned to Canada after recent hospitalization while visiting India.

full-text:
NDM-1 in Traveler, Canada | CDC EID


Suggested Citation for this Article
Peirano G, Ahmed-Bentley J, Woodford N, Pitout JDD. New Delhi metallo-β-lactamase from traveler returning to Canada. Emerg Infect Dis [serial on the Internet]. 2011 Feb [date cited]. http://www.cdc.gov/EID/content/17/2/242.htm



DOI: 10.3201/eid1702.101313


Comments to the Authors
Please use the form below to submit correspondence to the authors or contact them at the following address:

Johann D. Pitout, Calgary Laboratory Services, #9, 3535 Research Rd NW, Calgary, AB T2L 2K8, Canada; email: johann.pitout@cls.ab.ca